You are here: Industry Insights > Baricitinib

News List

Baricitinib in combination with remdesivir reduces recovery time in hospitalised COVID-19 patients: Study expresspharma
September 16, 2020
Data from the Adaptive COVID-19 Treatment Trial (ACTT-2) revealed an approximately one-day reduction in median recovery time for the overall patient population.
Lilly Begins Baricitinib Trial for Hospitalized COVID-19 Patients americanpharmaceuticalreview
June 24, 2020
Eli Lilly and Company announced the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte.
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients prnewswire
June 16, 2020
Eli Lilly and Company announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, ...
Montefiore, Einstein Test New Drug Combo to Conquer COVID-19 contractpharma
May 27, 2020
Researchers hope giving remdesivir along with a powerful anti-inflammatory could be the key to treating the most severe COVID-19 cases.
Eli Lilly’s COVID-19 therapies to enter clinical trials europeanpharmaceuticalreview
April 17, 2020
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
Lilly Begins Clinical Testing of Therapies for COVID-19 americanpharmaceuticalreview
April 15, 2020
Eli Lilly and Company has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Lilly, NIAID to Study Baricitinib in COVID-19 contractpharma
April 14, 2020
Baricitinib's anti-inflammatory activity has been hypothesized to have a potential benefit in COVID-19.
Eli Lilly receives breakthrough status for baricitinib in alopecia pharmaceutical-technology
March 18, 2020
Eli Lilly and its partner Incyte have received breakthrough therapy designation from the US Food and Drug Administration (FDA) for baricitinib to treat alopecia areata.
Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Derma americanpharmaceuticacreview
September 18, 2017
Eli Lilly and Company and Incyte announced new safety and efficacy data from a Phase 2 study of baricitinib in people with moderate-to-severe atopic dermatitis (AD).
Lilly, Incyte reveal earlier-than-expected refiling for baricitinib fiercebiotech
August 31, 2017
New application will include new safety and efficacy data.

Previous page 1 2 3 4 5 Next page